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Abstract
Background and Aim: The United Kingdom-primary biliary cholangitis (UK-PBC)
and global primary biliary cholangitis group (GLOBE) prognostic models have been
recently developed to predict long-term outcomes in primary biliary cholangitis
(PBC). However, these predictive scores have not yet been well evaluated in the
U.S. population.
Methods: We retrospectively reviewed newly diagnosed PBC patients at the Cleveland Clinic between November 1998 and February 2017. Adverse events were defined
as liver transplantation, liver-related mortality, and all-cause mortality. Transplant-free
survival (TFS) was estimated using the Kaplan–Meier method. Predictive performances of all prognostic models were evaluated using the C-statistic.
Results: We identified 352 patients who used ursodeoxycholic acid therapy. Of them,
311 (88.4%) only had PBC, while 41 (11.6%) were diagnosed with PBC-autoimmune
hepatitis overlap. A total of 22 (6%), 47 (13%), and 55 (16%) patients had adverse
events within 5, 10, and 15 years after diagnosis, respectively. In patients with PBC
only, the C-statistic in predicting 15-year adverse events was 0.75 per GLOBE compared to 0.74 per UK-PBC (P = 0.94), 0.73 per Rotterdam (P = 0.44), 0.66 per Barcelona (P = 0.004), 0.65 per Paris 1 (P = 0.005), 0.62 per Paris 2 (P < 0.0001), 0.60 per
Toronto (P < 0.0001), and 0.60 per Mayo (P < 0.0001) scores. Median follow-up was
9.2 years. Ten-year TFS for patients who had optimal versus suboptimal treatment
response was 92 versus 74% per Paris 1 (P < 0.0001), 95 versus 79% per Paris
2 (P = 0.0002), 93 versus 65% per Barcelona (P < 0.0001), and 96 versus 68% per
Rotterdam (P < 0.0001) risk scores, respectively.
Conclusion: In our cohort of PBC patients, the UK-PBC and GLOBE scores were
both accurate and reasonably valid prognostic models in the U.S. population.

Introduction
Primary biliary cholangitis (PBC), formerly known as primary
biliary cirrhosis,1 is an autoimmune liver disease characterized
by progressive lymphatic destruction of small intrahepatic biliary
ducts causing cholestasis. In the absence of effective therapy, it
frequently progresses to cirrhosis, which usually poses a poor
prognosis with a high risk of liver-related complications and
death.2 Previous studies have reported a wide-ranging prevalence
of PBC from 19 to 402 cases per million population,3 with a
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higher incidence in women (female to male ratio 8:1), typically
presenting between 30 and 65 years of age.4,5
The etiology of PBC is postulated to be due to an interplay of genetic predisposition and environmental triggers.6
Ursodeoxycholic acid (UDCA) therapy has been the first-line
standard of care for PBC patients since the Food And Drug
Administration (FDA) approval in 1997 with a recommended
dose of 13–15 mg/kg. It acts by modifying the bile acid pool and
reducing the levels of pro-inflammatory cytokines and vasoactive
mediators, thereby preventing apoptosis and cellular necrosis.7
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UDCA has been proven to be well-tolerated and highly effective
in delaying progression to end-stage liver disease (ESLD),
prolonging transplant-free survival (TFS) and overall survival
(OS).8–10 An alternative or adjunctive therapy with obeticholic
acid, a farnesoid X receptor antagonist, has been approved by the
FDA in May 2016 for UDCA nonresponders.11,12 Other medications such as colchicine, methotrexate, and mycophenolate
mofetil are currently under investigation.13,14
Multiple prognostic scores have been proposed by various
medical centers, mainly from Europe, to identify biochemical
and clinical predictors of survival after treatment with UDCA,
such as the Mayo risk score,15 Rotterdam criteria,16 Paris
1 criteria,17 Paris 2 criteria,18 Toronto criteria,19 and Barcelona
criteria.20 However, all of these scoring systems were developed
and validated in a local population, thus resulting in varied outcomes and limitations due to the complexity of PBC.21
Recently, two advanced scoring systems, the United
Kingdom-primary biliary cirrhosis (UK-PBC) and the global primary biliary cholangitis group (GLOBE) scores, have been developed using biochemical parameters at baseline and 1 year after the
introduction of UDCA therapy. The UK-PBC score was developed
in 2016 from a multicenter cohort of 1916 patients and validated
in a multicenter cohort of 1249 patients in the United Kingdom.22
In contrast, the GLOBE score was developed by combining raw
data from the above medical centers in addition to several other
countries, including Italy, Japan, and the United States. The
GLOBE score demonstrated a better C-statistic in derivation and
validation cohorts compared to the other scores. The GLOBE
score predicted 5-year and 10-year survival, with positive predictive values (PPVs) of 98 and 88%, respectively.23 However, the
reference population data were derived only from the Netherlands,
which might affect the external validity of this scoring system.
Notably, the GLOBE and UK-PBC scores provide more precise
and personalized estimates of the risk of developing ESLD within
defined time points in contrast to the other existing long-term
prognostic models that dichotomize patients into being at low risk
(treatment responders) or high risk (treatment nonresponders) of
developing ESLD at any point in time.
Use of the aforementioned advanced prognostic models in
patients with PBC has become a standard method to manage,
monitor, and risk stratify UDCA users.24 The advancements of
liver transplant and the development of alternative effective therapies for UDCA nonresponders have led to the wider use of
those biomarkers.25 For example, the application of those prognostic biomarkers allows for appropriate candidate selection of
second-line therapies and aids in identifying high-risk patients
for a closer follow-up or the consideration of liver transplant.
The current literature lacks any studies that externally validate these scoring systems exclusively in the American population.
Therefore, we conducted a retrospective study at our tertiary center
with complete biochemical data in an attempt to externally validate
the UK-PBC and GLOBE scoring systems for prognostication of
PBC among UDCA users in the U.S. population.

Methods
Patient selection and treatment protocols.
Electronic medical records of newly diagnosed PBC patients
between 1998 and 2017 at the Cleveland Clinic were reviewed.
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All patients were treated with 13–15 mg/kg daily of UDCA. We
excluded patients (i) younger than 18 years of age (n = 53);
(ii) those with concomitant alternative causes of liver disease
other than autoimmune hepatitis (n = 111); (iii) those with documented risky alcohol use within a year before PBC diagnosis
(n = 82); (iv) those with unavailable liver function tests at baseline or 1 year after initiation of UDCA (n = 182); and (v) those
unable to complete at least 1 year of UDCA due to side effects,
loss of follow-up, need of liver transplantation, or death
(n = 265). The protocol was approved by the institutional review
board of the Cleveland Clinic.
Diagnostic criteria, surveillance, and definitions.
PBC was diagnosed in the presence of at least two of the following three criteria1: serum alkaline phosphatase (ALP) levels
at least 1.5 times the upper limit of normal,2 positive test for
antimitochondrial antibody (AMA), and3 histological manifestations of portal area inflammation and bile duct injury.6 Histological staging of liver biopsy was performed as previously
defined.26
Autoimmune hepatitis–primary biliary cholangitis (AIHPBC) overlap syndrome was diagnosed in patients who fulfilled
the PBC diagnostic criteria in addition to two or more AIH
criteria1: alanine aminotransferase (ALT) levels more than five
times the upper limit of normal,2 serum immunoglobulin G levels
more than two times the upper limit of normal or a positive test
for antismooth muscle antibodies, and3 liver biopsy showing
moderate or severe periportal or periseptal lymphocytic piecemeal necrosis or interface hepatitis.
Patients were followed up every 3–6 months with complete blood count, basic metabolic panel, liver enzymes, albumin,
and bilirubin. Those with advanced-stage liver disease were
followed for prothrombin time, international normalized ratio,
and alpha-fetoprotein as well. If indicated, hepatocellular carcinoma (HCC) surveillance was performed with liver ultrasonography every 6 months, with HCC diagnosis by multiphase imaging
and/or histology. Cirrhosis was diagnosed with clinical evidence
of portal hypertension, hepatic decompensation, radiographic evidence of liver nodularity, or liver biopsy.27
Adverse events were defined as liver transplantation or
death from liver-related causes such as liver decompensation and
HCC. All-cause mortality was considered an adverse event for
the GLOBE score.23 Paris 1, Paris 2, Barcelona, Rotterdam,
Toronto, Mayo, GLOBE, and UK-PBC prognostic models were
used to assess response to UDCA and predict adverse events.
Statistical analysis. Baseline statistics were compared
between patients with and without adverse events using two
sample T-tests for continuous variables such as age, weight,
body mass index, and laboratory values. The Chi-square test or
Fisher’s exact test was used for categorical variables such as
gender, ethnicity, treatment response, and cirrhosis. OS was
calculated from the date of diagnosis to the date of death from
any cause, and TFS was calculated from the date of diagnosis
to the date of liver transplantation or liver-related death. Both
were estimated using the Kaplan–Meier method and compared
using the log-rank test. Predictive performances of all prognostic models for adverse events were evaluated using the
C-statistic representing the area under the receiver operating
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characteristic (ROC) curve, with larger values indicating better
discrimination. All statistical calculations were made using R
statistical software version 3.4.0 (R Foundation for Statistical
Computing, Vienna, Austria).

Results
Patient characteristics. Between November 1998 and
February 2017, 1045 patients with newly diagnosed PBC were
screened, and 693 patients were excluded as illustrated in
Figure 1; hence, 352 patients were included for analysis. Patient
and treatment characteristics are detailed in Table 1. The median
age at diagnosis was 55 years (range: 18–88); 50 (14%) patients
were male, and 319 (91%) were Caucasian. Forty-one (12%)
patients were diagnosed with AIH-PBC overlap syndrome. AMA
was positive for 313 (89%) patients, and smooth muscle antibodies were positive for 65 (26%) of 252 patients who were
tested for it. A total of 112 (18%) patients had cirrhosis at the
time of diagnosis. Of 259 (74%) patients who had a liver biopsy
at diagnosis, an actual biopsy report was available to review for
196 (56%) patients. Of these 196 patients, 7 (3%) had stage
0, 109 (56%) had stage 1 or 2 and 80 (41%) had stage 3 or
4 disease.
Evaluation of treatment response and validation
of prognostic models. The UDCA treatment response
rate was 73% per Paris 1, 55% per Paris 2, 83% per Barcelona, 72% per Rotterdam, 71% per Toronto, and 76% per
Mayo criteria. A total of 22 (6%), 47 (13%), and 55 (16%)
patients had adverse events within 5, 10, and 15 years after
diagnosis, respectively.
Area under the ROC curve in predicting 15-year adverse
events for patients with PBC only was 0.75 (95% confidence
interval [CI]: 0.66–0.83) per GLOBE score compared to 0.74
(95% CI: 0.66–0.83, P = 0.94) per UK-PBC, 0.73 (95% CI:
0.66–0.80, P = 0.44) per Rotterdam, 0.66 (95% CI: 0.58–0.73,
P = 0.004) per Barcelona, 0.65 (95% CI: 0.57–0.72, P = 0.005)

per Paris 1, 0.62 (95% CI: 0.55–0.69, P < 0.0001) per Paris
2, 0.60 (95% CI: 0.52–0.67, P < 0.0001) per Toronto, and 0.60
(95% CI: 0.52–0.67, P < 0.0001) per Mayo scores (Table 2).
For patients with AIH-PBC overlap syndrome, area
under the ROC curve in predicting 15-year adverse events was
0.79 (95% CI: 0.61–0.97) per Rotterdam score compared to
0.71 (95% CI: 0.49–0.94, P = 0.39) per GLOBE, 0.68 (95%
CI: 0.45–0.91, P = 0.31) per Barcelona, 0.66 (95% CI:
0.35–0.97, P = 0.36) per UK-PBC, 0.61 (95% CI: 0.38–0.84,
P = 0.10) per Paris 1, 0.55 (95% CI: 0.32–0.78, P = 0.033) per
Paris 2, and 0.51 (95% CI: 0.34–0.69, P = 0.014) per Mayo
scores (Table 3).
Overall and TFS. Median follow-up time was 9.2 years from
diagnosis. The 10-year OS for patients with and without baseline
cirrhosis was 81% (95% CI: 72.9–89.2) and 94% (95% CI:
90.5–97.8), respectively (P = 0.0011) (Fig. 2).
The 10-year OS for patients with PBC who had an optimal
versus suboptimal treatment response was 93% (95% CI:
89.8–97.4) versus 74% (95% CI: 63.5–86.2) per Paris
1 (P < 0.0001), 96% (95% CI: 92.9–99.6) versus 80% (95% CI:
72.1–87.7) per Paris 2 (P = 0.0002), 94% (95% CI: 90.2–97.3)
versus 65% (95% CI: 52.4–81.5) per Barcelona (P < 0.0001),
96% (95% CI: 93.3–99.3) versus 69% (95% CI: 58.6–81.2) per
Rotterdam (P < 0.0001), 93% (95% CI: 89.2–97.2) versus 78%
(95% CI: 68.1–88.2) per Toronto (P = 0.0008), and 92% (95%
CI: 88.2–96.3) versus 77% (95% CI: 66.3–89.1) per Mayo
(P = 0.003) risk scores (Fig. 3).
The 10-year TFS for patients with PBC who had an optimal versus suboptimal treatment response was 92% (95% CI:
88.3–96.3) versus 74% (95% CI: 63.6–85.8) per Paris
1 (P < 0.0001), 95% (95% CI: 90.8–98.3) versus 79% (95% CI:
72.1–87.5) per Paris 2 (P = 0.0002), 93% (95% CI: 89.0–96.4)
versus 65% (95% CI: 51.8–80.5) per Barcelona (P < 0.0001),
96% (95% CI: 92.4–98.7) versus 68% (95% CI: 57.5–79.8) per
Rotterdam (P < 0.0001), 92% (95% CI: 87.8–95.9) versus 78%
(95% CI: 68.3–88.2) per Toronto (P < 0.0008), and 91% (95%
CI: 86.8–95.1) versus 77% (95% CI: 66.5–89.2) per Mayo
(P = 0.003) risk scores (Fig. 4).

Discussion

Figure 1 Flow diagram of patient selection and treatment outcomes.
†
As per the National Institute on Alcohol Abuse and Alcoholism definition: Men under age 65: >14 drinks/week or >4 drinks/day. Women
and adults 65 years and older >7 drinks/week or >3 drinks/day. AIHPBC, autoimmune hepatitis–PBC, primary biliary cholangitis; UDCA,
ursodeoxycholic acid.
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Since the development of PBC advanced risk models (GLOBE
and UK-PBC scores), little is known about the accuracy and reliability of their use outside Europe. In this analysis, we found that
the Rotterdam criteria and both the UK-PBC and GLOBE scores
had good and comparable prognostic predictive values when
used in PBC or AIH-PBC overlap syndrome patients receiving
UDCA. In addition, the UK-PBC and GLOBE scoring systems
were superior (C-statistic of 0.7–0.75) to the other “treatment
response” criteria (exclusive of the Rotterdam criteria) in
predicting TFS of UDCA-treated patients with PBC. Therefore,
we conclude that the Rotterdam criteria, in addition to the UKPBC and GLOBE scores, are effective and can be generalized to
the U.S. population.
In our study, we recruited 311 patients with a confirmed
diagnosis of PBC only and 41 patients with AIH-PBC overlap
syndrome; the median overall age at diagnosis was 55 years,
which is similar to the reported mean age at diagnosis in other

JGH Open: An open access journal of gastroenterology and hepatology 4 (2020) 132–139
© 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and
John Wiley & Sons Australia, Ltd.

M Alomari et al.

Biomarkers in primary biliary cholangitis

Table 1 Patient and treatment characteristics

Characteristics
Demographics
Age (year), median (range)
Gender: female
Caucasian ethnicity
Body mass index (kg/m2), median (range)
Weight (kg), median (range)
Type of liver disease
Primary biliary cirrhosis
Overlap syndrome
Laboratory findings at diagnosis
Platelet (109/L), median (range)
Albumin (g/dL), median (range)
Bilirubin (mg/dL), median (range)
AST/ALT (U/L), median (range)
ALP (U/L), median (range)
AMA positivity
SMA positivity‡
Treatment response
Paris 1
Paris 2
Barcelona
Rotterdam
Toronto§
Mayo
Cirrhosis
Hepatic encephalopathy
Varices
Ascites

Patients with adverse
events†, n (%)

All patients, n (%)

Patients without
adverse events†, n (%)

P value

55 (6–88)
302 (85.8)
319 (91)
27 (13–54)
67 (30–100)

52 (14–88)
54 (79.4)
59 (87)
27 (17–53)
69 (39–100)

55 (6–87)
248 (87.3)
260 (92)
27 (13–54)
66 (30–94)

0.64
<0.0001
0.22
0.35
0.014
0.42

311 (88.4)
41 (11.6)

62 (91.2)
6 (8.8)

249 (87.7)
35 (12.3)

222 (7–713)
40 (17–54)
0.6 (0.1–32.2)
34 (6–694)
156 (32–1658)
313 (89)
65/252 (25.8)

131 (7–574)
33 (19–45)
2.2 (0.2–13.3)
40 (12–694)
187 (47–1658)
60 (88)
10/37 (27.0)

231 (20–713)
41 (17–54)
0.5 (0.1–32.2)
32 (6–596)
150 (32–1520)
253 (89)
55/215 (25.6)

<0.0001
<0.0001
<0.0001
0.037
0.028
0.26
0.85

258 (73.3)
195 (55.4)
292 (83.0)
254 (72.2)
251 (71.3)
269 (76.4)
112 (31.8)
62 (17.6)
78 (22.2)
63 (17.9)

34 (50.0)
25 (36.8)
39 (57.4)
23 (33.8)
42 (61.8)
45 (66.2)
50 (73.5)
37 (54.5)
37 (54.5)
32 (47.1)

224 (78.9)
170 (59.9)
253 (89.1)
231 (81.3)
209 (73.6)
224 (78.9)
62 (21.8)
25 (8.8)
41 (14.4)
31 (10.9)

<0.0001
0.001
<0.0001
<0.0001
0.053
0.027
<0.0001
<0.0001
<0.0001
<0.0001

†

Adverse event was defined as liver transplantation or liver-related death at any time.
Only 252 (72%) patients were tested.
§
Response according to Toronto criteria calculated after 2 years.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, antimitochondrial antibody; AST, aspartate aminotransferase; SMA, smooth muscle
antibody.
‡

western countries.28 However, on average, patients with adverse
events were diagnosed approximately 3 years earlier than the
noncomplicated PBC patients (52 vs 55 years). This finding is
supported by a cross-sectional study by Carbone et al.,29 where
they analyzed biochemical data for 2353 patients with PBC
receiving UDCA and found that the more symptomatic and lessresponsive disease to therapy was found in women presenting
before the age of 50 years. The majority of patients involved in
our study were females (85.8%),30 in line with the previously
reported numbers in the western population. Among the studied
patients, 13 (5.4%) developed PBC recurrence after liver transplantation in contrast to the conveyed PBC recurrence rate of
8–30%.31 This significant discrepancy could be related to the
lack of uniform diagnostic criteria for PBC recurrence, the
increased use of prophylactic UDCA after liver transplantation,32
and the advancement in posttransplant immunosuppressive therapy.33 Cirrhosis was present at diagnosis in 31.8% of our study
patients compared to 28.5% of the involved cases in a study by
Cheung et al..34 Expectedly, when stratified for baseline cirrhosis, the 10-year OS was significantly lower among cirrhotic
patients, 81 versus 94% (P = 0.0011). Notably, our cohort OS

was slightly higher than that reported by the Lammers et al.
meta-analysis,28 with 92, 83, and 72 versus 90%, 78%, and 66%
at 5, 10, and 15 years, respectively. This difference may be caused by early detection, improvement of PBC natural history, and
advances in the management of liver-related complications and
liver transplantation in recent years.35 Although liver histology is
not necessary for the diagnosis of PBC,36 it has an important
prognostic significance.37 The studied cohort represents a heterogeneous sample of early histological disease (stages 0, 1, and 2;
63%) and advanced histological disease (stages 3 and 4; 41%).
In comparison to the derivation group of the GLOBE study,23
where 39.5% had available liver biopsy results, among them,
55.9% had early disease, while 25.7% were found to have
advanced disease. HCC was diagnosed in 0.28% of our involved
patients, and this number is similar to the observed prevalence of
0.34% in a multicenter, international study by Trivedi et al.38
involving 4565 patients with a follow-up period of more than
40 years.
In our study, evaluation of the advanced prognostic
models demonstrated an overall performance (measured by Cstatistic) of 0.75 for the GLOBE score in contrast with 0.82 in
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Predictive performances of prognostic models for adverse events in patients with primary biliary cholangitis

Event within 5 years
C-statistic
95% CI
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)
Event within 10 years
C-statistic
95% CI
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)
Event within 15 years
C-statistic
95% CI
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)

Paris 1

Paris 2

Barcelona

Rotterdam

Toronto

Mayo

GLOBE

UK-PBC

0.62
0.50–0.73
48
76
12
95

0.57
0.45–0.68
57
56
9
95

0.64
0.53–0.75
43
85
17
95

0.74
0.64–0.84
71
76
18
97

0.54
0.43–0.65
38
70
9
94

0.52
0.42–0.62
29
76
8
94

0.73
0.61–0.86
—
—
—
—

0.70
0.57–0.82
—
—
—
—

0.66
0.58–0.74
53
78
28
91

0.63
0.55–0.71
67
59
21
92

0.67
0.60–0.75
47
88
38
91

0.75
0.67–0.82
70
80
36
94

0.59
0.51–0.67
47
72
21
89

0.59
0.51–0.67
40
78
22
89

0.75
0.65–0.84
—
—
—
—

0.75
0.66–0.84
—
—
—
—

0.65
0.57–0.72
51
79
31
90

0.62
0.55–0.69
65
59
23
90

0.66
0.58–0.73
43
88
40
89

0.73
0.66–0.80
65
80
38
93

0.60
0.52–0.67
50
73
24
88

0.60
0.52–0.67
41
78
26
88

0.75
0.66–0.83
—
—
—
—

0.74
0.66–0.83
—
—
—
—

CI, confidence interval; GLOBE, global primary biliary cholangitis group; NPV, negative predictive value; PPV, positive predictive value; UK-PBC,
United Kingdom-primary biliary cholangitis.

Table 3

Predictive performances of prognostic models for adverse events in patients with overlap syndrome

Event within 5 years
C-statistic
95% CI
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)
Event within 10 years
C-statistic
95% CI
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)
Event within 15 years
C-statistic
95% CI
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)

Paris 1

Paris 2

Barcelona

Rotterdam

0.34
NA
0
68
0
96

Toronto

Mayo

GLOBE

UK-PBC

0.29
NA
0
58
0
96

0.40
NA
0
80
0
97

0.84
NA
100
68
7
100

0.41
NA
0
83
0
97

0.43
NA
0
85
0
97

0.65
NA
—
—
—
—

0.88
NA
—
—
—
—

0.46
0.21–0.72
25
68
8
89

0.41
0.15–0.67
25
57
6
88

0.53
0.28–0.78
25
81
13
91

0.73
0.47–0.98
75
70
21
96

0.54
0.29–0.80
25
84
14
91

0.56
0.31–0.81
25
86
17
91

0.58
0.32–0.84
—
—
—
—

0.53
0.19–0.88
—
—
—
—

0.61
0.38–0.84
50
71
23
89

0.55
0.32–0.78
50
60
18
88

0.68
0.45–0.91
50
86
38
91

0.79
0.61–0.97
83
74
36
96

0.50
0.32–0.67
17
83
14
85

0.51
0.34–0.69
17
86
17
86

0.71
0.49–0.94
—
—
—
—

0.66
0.35–0.97
—
—
—
—

CI, confidence interval; GLOBE, global primary biliary cholangitis group; NA, not available; NPV, negative predictive value; PPV, positive predictive
value; UK-PBC, United Kingdom-primary biliary cholangitis.

the GLOBE validation cohort23 and an overall performance of
UK-PBC score of 0.70, 0.75, and 0.74 versus 0.96, 0.95, and
0.94 after 5, 10, and 15 years, respectively, in the prospective
validation cohort.22 However, there was no statistically
136

significant difference between the two scoring models as their
CIs overlap. We also evaluated the performance of treatment
response criteria after 1 year of UDCA treatment with the exception of the Toronto criteria, which was measured after 2 years of
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Figure 2 Overall survival of patients with baseline cirrhosis (gray line)
and without baseline cirrhosis (black line).

Biomarkers in primary biliary cholangitis

therapy, and the calculated C-statistic ranged between 0.54 and
0.75. Among the above criteria, the Toronto criteria had the lowest overall predictive value, while the Rotterdam criteria outperformed the other criteria in predicting adverse events. The
better performance of the GLOBE and UK-PBC scores compared
to the other treatment response criteria (with the exception of
the Rotterdam criteria) might be due to the use of continuous,
instead of categorical, variables, which include important factors
that reflect liver synthetic function (albumin), portal hypertension/cirrhosis (platelet count), biliary disease (ALP and bilirubin), and the patient’s age.28,29,39 Furthermore, the advanced
models are based on baseline and 1-year posttreatment disease
analysis, while the treatment response criteria only evaluate the
posttreatment disease.
Consistent with prior studies,23,34 all biomarker prognostic
models showed a relatively high negative predictive value (NPV)
(>93% at 5 years, >87% at 10 years, and >84% at 15 years) but a
low PPV (<19% at 5 years, <39% at 10 years, and <41% at

Figure 3 Overall survival of patients with primary biliary cholangitis (black line) and overlap syndrome (gray line) in response (----- line) and no
response (- - - line) cohorts based on risk scores. (a) Paris-1, (b) Paris-2, (c) Barcelona, (d) Rotterdam, (e) Toronto, and (f) Mayo.
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Figure 4 Transplant-free survival of patients with primary biliary cholangitis (black line) and overlap syndrome (gray line) in response (----- line) and
no response (- - - line) cohorts based on risk scores. (a) Paris-1, (b) Paris-2, (c) Barcelona, (d) Rotterdam, (e) Toronto, and (f) Mayo.

15 years) in predicting adverse events. Generally, as the disease
progresses, the NPV decreases, while the PPV increases. Among
treatment response criteria, the Rotterdam and Barcelona criteria
are considered good predictors of good overall prognosis.
The present study has several limitations, including the
retrospective nature of the data collection with its inherent biases.
Moreover, our study represents a single tertiary center experience
that is liver transplant-capable, which might generate selection
bias. However, manual review of all cases and application of
strict inclusion and exclusion criteria largely contributed to eliminating questionable diagnoses to the greatest extent possible in a
retrospective study. In addition, the long follow-up period, with a
median of 9.2 years, allowed for an accurate analysis of adverse
events and liver-related/overall mortality.
In conclusion, the Rotterdam criteria and the UK-PBC
and GLOBE scores outperformed the other risk scores for
predicting OS and TFS in patients with PBC who were treated
with UDCA for at least 1 year. In addition, they were both
accurate and valid for use as prognostic models in the
U.S. population.
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